Replies to post #108193 on Biotech Values

[RockRat]

>>Let us say that they now the technology to characterise the product as well as momenta. they would have to go to the batches that they used in their filing seven years ago. What are the chances that those batches, after being characterised would fall into the ranges of the Sanofi product? <<

Zero, including the reason that those batches are long since expired and degraded. They would make new batches and characterize them with this technology. And as I have stated, Teva will not likely be using the same process(drug) as they used seven years ago. They certainly won't be using the Lupenox process, if they ever did.

Regards, RockRat